Adult Dosing

Treatment of corticosteroid responsive dermatoses

• Apply to affected area(s) bid–tid depending upon infection

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Steroid responsive inflammatory and pruritic dermatoses

• Hypersensitivity to any of the components of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia and glucosuria have occurred due to systemic absorption of topical corticosteroid
• Application of the more potent steroids, large surface areas, prolonged use and occlusive dressing add on to the systemic absorption
• Monitor the patients for HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests, discontinue or reduce the frequency of application, or substitute with a less potent steroid if HPA- axis suppression noted
• Discontinue the drug if any irritation develops
• Not for ophthalmic use
• In case of any dermatological infection, appropriate antifungal or antibacterial agent should be used
• Pediatric patients are more susceptible to systemic toxicity (HPA axis suppression, Cushing syndrome and intracranial hypertension) as proportionally larger amounts of topical corticosteroids is absorbed
• Limit the use of topical corticosteroid in pediatric patients to the least amount compatible with an effective therapeutic regimen
• Long term corticosteroid therapy in pediatric patients may interfere with their growth and development

Cautions: Use cautiously in

• Pediatric patients
• Skin infection

Supplemental Patient Information

• Patients are advised to avoid contact with the eyes
• Should not use the medication for any disorder other than for which it was prescribed
• Should not wrap or bandage the treated skin area unless advised by the physician
• Report to the clinician if there is any sign of local adverse reaction
• Parents of pediatric patient, being treated in the diaper area should not use tight-fitting diapers or plastic pants

Pregnancy Category:C

Breastfeeding: No published data; short-term application of topical corticosteroids is not expected to pose a risk to the breastfed infant by passage into breastmilk. Use of the least potent drug on the smallest area of skin of mother is recommended. Ensure that the infant's skin does not come into direct contact with the areas treated with this drug. Use of lower potency corticosteroids, water-miscible cream products on the nipple or areola is recommended. Any topical corticosteroid should be wiped off thoroughly prior to nursing if it is applied to the nipple or areola. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 30 November 2010). Manufacturer recommends discontinuation of nursing or discontinuation of therapy, by analyzing risk and benefit ratio in nursing mothers.

• DERM: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruption, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of skin, secondary infection, skin atrophy, striae, miliaria
• ENDO: Adrenal suppression, Cushing syndrome
• METABOLIC: Hyperglycemia
• CNS: Intracranial hypertension

• Corticosteroids; exact mechanism of action unknown, inhibits potent mediators of inflammation, prostaglandins and leukotrienes
• Minimally absorbed following topical application. Inflammation and occlusive dressings increase percutaneous absorption
• Metabolized by Liver; CYP450: Unknown
• Renally excreted
• Half-life: Unknown

US Trade Name(s)

• Only generic available

US Availability

amcinonide (generic)

• CRE: 0.1%
• OINT: 0.1%
• LOTN: 0.1%

Canadian Trade Name(s)

• Cyclocort

Canadian Availability

amcinonide (generic)

• CRE: 0.1%
• OINT: 0.1%
• LOTN: 0.1%

Cyclocort

• CRE: 0.1%
• OINT: 0.1%
• LOTN: 0.1%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Steroids

Pricing data from www.DrugStore.com in U.S.A.

• Amcinonide 0.1 % CREA [Tube] (FOUGERA)
  60 % = $145.99
  180 % = $423.97
• Amcinonide 0.1 % CREA [Tube] (FOUGERA)
  15 % = $32.99
  45 % = $98.97
• Amcinonide 0.1 % CREA [Tube] (FOUGERA)
  30 % = $45.99
  90 % = $119.97
• Amcinonide 0.1 % OINT [Tube] (FOUGERA)
  60 % = $181.99
  180 % = $517.98

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.